Below are the financial statements of Iovance Biotherapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | — | — | — |
| Product revenue | 164.07a | 1.19a | 0a |
| Total revenue | 164.07a | 1.19a | 0a |
| Costs and expenses | — | — | — |
| Cost of sales | -124a | -10.76a | 0a |
| Research and development | -282.34a | -344.08a | -294.78a |
| Selling, general, and administrative | -153.02a | -106.92a | -104.1a |
| Total costs and expenses | -559.35a | -461.75a | -398.88a |
| Loss from operations | -395.28a | -460.56a | -398.88a |
| Other income | — | — | — |
| Interest and other income, net | 20.27a | 13.04a | 2.99a |
| Net loss before income taxes | -375.01a | -447.52a | -395.89a |
| Income tax benefit | 2.83a | 3.48a | 0a |
| Net loss | -372.18a | -444.04a | -395.89a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Iovance Biotherapeutics’s data sources below and access millions more through our Disclosure Search.